SC dismisses Novartis’s Patent Plea on Cancer Drug
In a huge blow to Swiss drug maker Novartis, the Supreme Court of India on Monday dismissed its plea for a patent on its cancer drug Glivec. The ruling suggested that the cancer drug, which costs Rs 1.2 lakh for a monthly dosage, would be…